Financial Performance - The company's operating revenue for 2021 was RMB 324,202,622.53, representing a 24.47% increase compared to RMB 260,468,434.47 in 2020[19]. - The net profit attributable to shareholders in 2021 was RMB 38,882,189.38, a significant increase of 128.87% from RMB 16,988,641.81 in the previous year[19]. - The net profit after deducting non-recurring gains and losses was RMB 25,214,668.12, up 155.84% from RMB 9,855,541.21 in 2020[19]. - The company's total assets increased by 51.84% to RMB 1,138,209,210.53 at the end of 2021, compared to RMB 749,631,868.84 at the end of 2020[19]. - The net assets attributable to shareholders rose by 83.23% to RMB 813,994,073.02 at the end of 2021, up from RMB 444,239,449.04 in 2020[19]. - The basic earnings per share for 2021 was RMB 0.1594, reflecting a 112.25% increase from RMB 0.0751 in 2020[19]. - The diluted earnings per share was RMB 0.1588, also up 112.02% from RMB 0.0749 in the previous year[19]. - The net cash flow from operating activities decreased by 68.99% to RMB 30,101,746.56 in 2021, down from RMB 97,067,618.03 in 2020[19]. - The company reported a weighted average return on equity of 6.26% for 2021, an increase of 2.32 percentage points from 3.94% in 2020[19]. Business Strategy and Expansion - The company is expanding its business into preclinical research and CDMO services, facing competition from established firms in these areas[6]. - The company aims to enhance its core competitiveness through strategic planning and leveraging its full industry chain service advantages[5]. - The company is focusing on developing innovative drug clinical services and preclinical services to mitigate risks associated with market competition[4]. - The company is committed to strengthening internal management and integrating professional management talent to improve operational efficiency[6]. - The company is focused on providing comprehensive "one-stop" CRO services, including preclinical research, clinical research, and CDMO services[36]. - The company plans to strengthen its clinical research services, particularly in liver disease, oncology, and respiratory fields, while expanding into cell and gene therapy research[110]. - The company aims to develop a comprehensive new drug research platform integrating drug research, clinical trials, and production, enhancing its competitive edge in the CRO industry[108]. - The company is actively seeking acquisition targets in niche markets to achieve rapid expansion[112]. Research and Development - The company has established six major R&D service platforms, enhancing its capabilities in traditional Chinese medicine and chemical drug research[56]. - The company has received multiple government grants for its R&D platforms, indicating strong support for its innovation efforts[57]. - The company has developed over 30 drug research projects, obtaining 3 production licenses and 5 clinical research approvals[145]. - The company has filed nearly 20 patents and published over 30 academic articles related to drug development[145]. - The company is advancing its KHK target compound screening system, which is expected to meet the demand for innovative fatty liver treatments[78]. - The company has established partnerships with various academic and research institutions to enhance innovation[145]. Market and Competition - The CRO market is projected to reach USD 64.58 billion by 2021, with a compound annual growth rate (CAGR) of 12.8% from 2016 to 2021[30]. - The Chinese CRO market is expected to grow from USD 6.8 billion in 2019 to USD 22.2 billion by 2024, with a CAGR of approximately 26.5%[31]. - The company acknowledges the increasing market competition in the CRO industry, necessitating higher marketing and service standards[5]. Governance and Compliance - The company has established and improved its governance structure in compliance with relevant laws and regulations, ensuring effective decision-making and compliance[117]. - The board of directors consists of 7 members, including 3 independent directors, meeting legal and regulatory requirements[118]. - The company maintains independence from its controlling shareholder, with no instances of fund occupation or guarantees provided to the controlling shareholder[122]. - The company has established a complete and independent financial accounting system, ensuring independent financial decision-making[122]. - The company has not faced any penalties from regulatory bodies regarding internal control issues during the reporting period[121]. Employee and Management - The workforce increased from over 700 to approximately 1,000 employees, a growth of about 38%, with the recruitment of 9 PhDs in various fields[46]. - The total number of employees at the end of the reporting period was 989, with 384 in the parent company and 605 in major subsidiaries[165]. - The company has established a comprehensive training system to enhance employee skills and capabilities, aligning with business needs[168]. - The company has implemented a differentiated compensation policy based on department and job nature, aiming for performance-oriented salary management[167]. Financial Management - The company raised a total of CNY 343 million through the issuance of 33.45 million shares, aimed at enhancing CDMO platform construction and clinical research service capabilities[38]. - The company reported a credit impairment loss of -5,309,692.89, which accounted for -11.28% of total profit, primarily due to bad debt losses[84]. - The company has established measures to ensure the fulfillment of immediate return commitments, with legal responsibilities for any violations[200]. Shareholder and Dividend Policy - The company plans to distribute a cash dividend of 0.20 RMB per 10 shares and a capital reserve increase of 4 shares per 10 shares to all shareholders[6]. - The cash dividend amount for the year was CNY 5,229,363.30, representing 100% of the total profit distribution[170]. - The company plans to issue 4 new shares for every 10 shares held as part of its capital reserve conversion plan[169].

博济医药科技股份有限公司 2021 年第三季度报告 □ 是 √ 否 证券代码：300404 证券简称：博济医药 公告编号：2021-085 博济医药科技股份有限公司 2021 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 重要内容提示: 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、 误导性陈述或重大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信 息的真实、准确、完整。 3.第三季度报告是否经过审计 一、主要财务数据 (一)主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 本报告期比上年同期增 | 年初至报告期末 | 年初至报告期末比上年 | | --- | --- | --- | --- | --- | | | | 减 | | 同期增减 | | 营业收入（元） | 94,026,593.42 | 40.47% | 214,793,258.50 | 21.36% ...

Financial Performance - The company reported a total revenue of RMB 300 million for the first half of 2021, representing a year-on-year increase of 15% compared to the same period in 2020[14]. - The net profit attributable to shareholders for the first half of 2021 was RMB 50 million, an increase of 20% year-on-year[14]. - The management has set a revenue target of RMB 600 million for the full year 2021, reflecting a growth rate of 20%[14]. - The company achieved total operating revenue of 120,766,665.08 CNY, an increase of 9.74% compared to the same period last year[34]. - Net profit attributable to shareholders was 14,077,398.68 CNY, representing an 18.55% increase year-over-year[34]. - The company reported a total comprehensive income of CNY 16,444,393.82 for the first half of 2021, compared to CNY 15,080,552.18 in the same period of 2020[180]. - The company reported a net profit for the first half of 2021 of CNY 10,481,013.74, a decrease of 15.7% compared to CNY 12,432,465.60 in the same period of 2020[183]. - The company reported a total cash inflow from financing activities of CNY 368,760,838.34, compared to CNY 49,727,636.05 in the previous year, indicating a strong financing position[190]. Research and Development - The company plans to invest RMB 100 million in research and development for new drug technologies in the upcoming year[14]. - Research and development expenses rose by 14.95% to ¥12,342,227.62 from ¥10,737,338.09, reflecting ongoing investment in innovation[57]. - The company has developed a new drug, a fluconazole ear drop, which has received a patent certificate from the National Intellectual Property Administration[41]. - The company plans to continue its research and development efforts in new products and technologies[196]. - The company’s R&D expenditure for the first half of 2021 was approximately 5,000 million yuan, reflecting its commitment to innovation and product development[200]. Market Expansion and Strategy - User data indicates a growth in the customer base by 25%, reaching a total of 10,000 active users by the end of June 2021[14]. - The company has expanded its market presence by entering two new provinces, increasing its operational footprint by 30%[14]. - The company is actively pursuing partnerships with international firms to leverage new technologies and expand its research capabilities[14]. - The company is focusing on expanding its market presence and enhancing its product offerings through ongoing research and development initiatives[170]. - The company aims to expand its market presence through strategic partnerships and potential acquisitions in the healthcare sector[200]. Financial Health and Investments - Total assets at the end of the reporting period were 1,088,411,313.70 CNY, a 45.19% increase from the end of the previous year[34]. - The net assets attributable to shareholders reached 776,596,497.02 CNY, up 74.81% from the previous year[34]. - The company reported a significant increase in cash flow, with cash and cash equivalents nearly tripling compared to the previous period[170]. - The company has committed to invest 10,681.59 million yuan in the CDMO platform construction project, with no funds utilized to date[76]. - The company plans to continue its investment strategy, focusing on expanding its market presence and enhancing product development capabilities[190]. Risks and Challenges - The company faces risks related to contract execution in new drug development, including potential delays and terminations due to unmet research expectations and changes in client direction[89]. - The rapid growth of domestic CRO companies has intensified competition in the pharmaceutical R&D outsourcing industry, necessitating improved marketing and service levels[90]. - New business expansions into preclinical research and CDMO services may face challenges due to existing competitive companies and the company's limited experience in these areas[91]. Shareholder and Equity Information - The company has not distributed cash dividends for the current fiscal year, focusing instead on reinvestment[4]. - The company’s stock option incentive plan allowed for the exercise of 1,252,290 shares during the second exercise period, impacting earnings per share and net assets per share[144]. - The largest shareholder, Wang Tingchun, holds 30.85% of the shares, amounting to 80,618,642 shares, with 20,154,661 shares pledged[153]. - The company has a total of 17,767 ordinary shareholders as of the end of the reporting period[153]. - The company’s major shareholders have a total of 60,463,981 shares under lock-up, with a release schedule of 25% annually[145]. Legal and Compliance - The company reported a lawsuit involving its wholly-owned subsidiary with a claim amount of 2.5995 million yuan, currently in the second instance stage, which is not expected to significantly impact operations[113]. - The company has not faced any significant environmental issues or administrative penalties during the reporting period[103]. - The financial report for the first half of 2021 was not audited, indicating a potential area of concern for investors[167].

Financial Performance - The company's revenue for Q1 2021 was ¥55,245,275.36, representing a 165.36% increase compared to ¥20,818,697.66 in the same period last year[8] - Net profit attributable to shareholders was ¥7,369,156.02, a significant turnaround from a loss of ¥5,863,094.83, marking a 225.69% increase[8] - The net profit after deducting non-recurring gains and losses was ¥2,880,893.96, compared to a loss of ¥7,519,974.54, reflecting a 138.31% improvement[8] - Basic earnings per share were ¥0.0325, up 225.00% from -¥0.0260 in the same quarter last year[8] - The company reported a total sales revenue of 12,518,428.88 yuan, accounting for 22.67% of its total operating income[26] - The total operating revenue for the first quarter reached CNY 55,245,275.36, a significant increase from CNY 20,818,697.66 in the previous period[47] - The net profit for the first quarter reached CNY 9,899,292.90, a turnaround from a net loss of CNY 5,698,021.32 in the same period last year[49] - The company's operating profit was CNY 11,126,644.32, compared to an operating loss of CNY 7,242,531.16 in the previous year[49] - The total comprehensive income for the quarter was CNY 10,081,451.44, compared to a loss of CNY 5,485,594.15 in the previous year[50] Cash Flow - The net cash flow from operating activities reached ¥7,490,830.80, a substantial increase of 1,514.39% from -¥529,616.16 in the previous year[8] - The cash inflow from operating activities amounted to CNY 70,467,706.01, an increase from CNY 44,149,562.53 in the previous period, representing a growth of approximately 59.5%[56] - The net cash flow from operating activities was CNY 7,490,830.80, recovering from a negative CNY 529,616.16 in the prior period[57] - The total cash outflow from investing activities was CNY 69,796,489.65, significantly higher than CNY 9,946,990.39 in the previous period, leading to a net cash flow from investing activities of -CNY 11,440,909.02[57] - Cash inflow from financing activities totaled CNY 16,480,000.00, down from CNY 20,115,000.00 in the previous period, resulting in a net cash flow from financing activities of -CNY 5,097,434.12[58] - The ending balance of cash and cash equivalents was CNY 137,507,691.92, compared to CNY 80,808,720.47 at the end of the previous period, indicating a significant increase[58] Assets and Liabilities - Total assets at the end of the reporting period were ¥759,934,380.33, an increase of 1.37% from ¥749,631,868.84 at the end of the previous year[8] - The total liabilities decreased slightly to CNY 263,630,226.54 from CNY 264,636,745.37, indicating a reduction of about 0.38%[41] - The company's equity attributable to shareholders reached CNY 452,929,084.80, up from CNY 444,239,449.04, reflecting an increase of about 1.56%[42] - The total non-current liabilities were CNY 18,723,076.22, with an adjustment of CNY 1,242,203.98 due to the new leasing standards[65] - The company reported a total of CNY 643,680,859.69 in total assets for the first quarter of 2021[68] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 19,132[12] - The largest shareholder, Wang Tingchun, holds 35.57% of the shares, with 60,463,981 shares pledged[12] - Net assets attributable to shareholders increased by 1.96% to ¥452,929,084.80 from ¥444,239,449.04 at the end of the last year[8] Business Operations - The company signed new contracts worth approximately ¥100 million during the reporting period, reflecting a year-on-year growth of about 146%[21] - The company is actively adjusting its business structure in response to potential policy changes in the pharmaceutical industry to mitigate risks[25] - The company is expanding its business into preclinical research and CDMO services, facing competition from established firms in these areas[29] - The company has signed contracts that allow for additional service fees under certain conditions to mitigate risks associated with budget overruns[27] Research and Development - Research and development expenses rose to ¥6,513,359.61, a 32.91% increase, as the company intensified its R&D investments[18] - The company reported a significant increase in other income, totaling ¥5,646,067.64, which is a 174.97% increase due to government subsidies related to daily activities[18] Risk Management - The company is facing risks related to contract execution, including potential delays and terminations due to clinical research failures or changes in client research directions[26] - The company has established a specific responsibility assumption model for project delays to manage risks effectively[28] - The company is enhancing its internal management and operational efficiency to address risks associated with its expanding business scale[29] - The company experienced a credit impairment loss of CNY 1,526,077.90, compared to a reversal of CNY -1,034,789.10 in the previous year, indicating potential credit risk issues[48] Compliance and Standards - The company has not reported any violations regarding external guarantees during the reporting period[34] - The company has implemented the new leasing standards effective January 1, 2021, impacting the financial statements[69] - The first quarter report for 2021 was not audited[70]

Financial Performance - The company reported a total revenue of 226,619,451, with no cash dividends or bonus shares distributed to shareholders[6]. - The company's operating revenue for 2020 was RMB 260,468,434.47, an increase of 16.25% compared to RMB 224,064,704.39 in 2019[19]. - The net profit attributable to shareholders for 2020 was RMB 16,988,641.81, representing a significant increase of 157.69% from RMB 6,592,620.34 in the previous year[19]. - The net profit after deducting non-recurring gains and losses was RMB 9,855,541.21, up 436.39% from RMB 1,837,396.93 in 2019[19]. - The net cash flow from operating activities reached RMB 97,067,618.03, a remarkable increase of 112,933.87% compared to RMB 85,874.81 in 2019[19]. - The total assets at the end of 2020 were RMB 749,631,868.84, an 18.41% increase from RMB 633,081,946.60 at the end of 2019[19]. - The net assets attributable to shareholders increased by 5.11% to RMB 444,239,449.04 from RMB 422,651,741.36 in 2019[19]. - The basic earnings per share for 2020 was RMB 0.0751, a 157.19% increase from RMB 0.0292 in 2019[19]. - The diluted earnings per share for 2020 was RMB 0.0746, reflecting a 157.24% increase from RMB 0.0290 in the previous year[19]. - The company reported a total of RMB 8,568,324.18 in government subsidies, which was an increase from RMB 4,621,895.60 in 2019[25]. Business Strategy and Development - The company plans to leverage its unique "one-stop" service advantage to adjust its business structure and development direction in response to policy changes in the new drug approval process[4]. - The company aims to enhance its risk resistance by developing innovative drug clinical services and preclinical services, capitalizing on its industry experience and talent[4]. - The company is expanding its business into preclinical research services and CDMO services, facing potential risks due to competition and lack of experience in these areas[6]. - The company emphasizes the importance of internal management and integration to mitigate risks associated with its expanding business scale[6]. - The company plans to strengthen internal training and talent reserves to adapt to changing policies and enhance operational efficiency[4]. - The company is actively developing innovative drug projects, including a ketone sugar kinase inhibitor, which has entered the CMC pharmaceutical research phase[56]. - The company is focusing on developing clinical research services for medical devices and diagnostic formulations to broaden its service offerings[104]. - The company plans to enhance its GLP drug evaluation center's business capabilities to better serve clients[105]. - The company intends to accelerate international expansion through acquisitions of overseas clinical CRO companies[105]. Market Competition and Risks - The rapid growth of domestic CRO companies has intensified market competition, prompting the company to improve its marketing and service levels[5]. - The company acknowledges the risk of contract execution delays due to the complex nature of new drug development, which may lead to budget management challenges[5]. - The company faces risks related to contract execution, including potential delays and cost overruns due to the long duration of drug development projects[108]. - The company has established specific responsibility models in contracts to address potential delays and associated penalties[5]. - The company is cautious in evaluating project execution difficulties before undertaking new projects to mitigate risks associated with new business expansions[111]. - The company has faced management risks due to the expansion of its operational scale and business scope, prompting efforts to enhance internal management and operational efficiency[111]. Research and Development - The company has developed multiple research platforms for traditional Chinese medicine and chemical drugs, enhancing its R&D capabilities[81]. - The company has established a comprehensive preclinical "one-stop" service research system, integrating process, quality, efficacy, pharmacokinetics, and toxicology evaluations[47]. - The company has completed multiple pharmacological and toxicological evaluations for its self-developed projects, including CRAT, ASP, and RUN[83]. - The company aims to obtain 1-2 new drug clinical approval documents annually to enhance its independent research and development capabilities[105]. - The company is conducting clinical research for a new drug targeting drug-resistant lung cancer, with an IND application submitted to the FDA[82]. Shareholder and Financial Management - The company has not proposed any cash dividends, stock bonuses, or capital reserve transfers for the 2020 fiscal year, opting to retain earnings for future investments[117]. - The company has committed to maintaining shareholder interests by not distributing dividends while planning for significant future expenditures[120]. - The company reported a cash dividend of RMB 226,619,451.00 for the year, with a total distributable profit of RMB 112,158,270.72, resulting in a cash dividend ratio of 0.00%[116]. - The company has fulfilled all commitments made by actual controllers and shareholders during the reporting period[122]. - The company has established a commitment to not transfer more than 25% of shares held during the tenure of directors and senior management[122]. - The company has ensured compliance with share transfer commitments to avoid changes in control and ensure long-term stability[124]. Corporate Governance and Compliance - The company emphasizes compliance with laws and regulations, ensuring the protection of stakeholders' rights, including suppliers and creditors[168]. - The company has made commitments to conduct related party transactions under fair and normal commercial conditions[124]. - The company has ensured strict compliance with commitments made by its controlling shareholders to avoid conflicts of interest[126]. - The company has stated that it will provide supplementary commitments in accordance with the latest regulations from securities regulatory agencies if necessary[128]. Subsidiaries and Investments - The company established several new subsidiaries, including Shenzhen Borui Pharmaceutical Technology Co., Ltd. and Jiangxi Bokang Pharmaceutical Technology Co., Ltd., which were included in the consolidated financial statements[137]. - The company participated in a new drug industry investment fund, with the controlling shareholder investing 37 million in the fund[149]. - The company’s wholly-owned subsidiary invested 9 million in the establishment of the Ganjiang New Area Boqu Investment Management Partnership[150]. - The company’s subsidiary, Guangzhou Boji Biological Pharmaceutical Technology Park Co., Ltd., increased its registered capital from 115 million RMB to 121.571 million RMB, with the company's shareholding reduced from 100% to 94.59%[177]. Stock Options and Share Capital - The company completed the first exercise period of its 2019 stock option incentive plan, with 980,655 options available for exercise[142]. - The company approved a new stock option incentive plan for 2020, granting 2.5 million options to 74 eligible participants[144]. - The total number of shares increased from 173,342,000 to 226,619,451 due to the implementation of the 2019 stock option incentive plan and capital reserve conversion[181]. - The company distributed a cash dividend of RMB 0.1 per 10 shares, totaling RMB 1,733,420, and converted 52,296,796 shares from capital reserves[185].

Financial Performance - Operating revenue for the period reached CNY 66,938,495.11, a 37.21% increase year-on-year[7] - Net profit attributable to shareholders surged by 185.62% to CNY 7,592,319.58 for the quarter[7] - Basic earnings per share rose by 184.75% to CNY 0.0336[7] - Operating profit surged by 268.67% to ¥28,229,425.03 driven by increased revenue and improved gross margin[19] - Net profit increased by 255.56% to ¥24,437,211.89 reflecting higher operating income and gross margin[21] - The total comprehensive income rose by 219.20% to ¥23,587,317.77, mainly due to the increase in net profit[21] - The total profit for the quarter was CNY 11,397,889.14, significantly higher than CNY 4,326,227.29 in the same quarter last year[48] - The net profit for the third quarter reached CNY 9,571,092.22, compared to CNY 3,600,393.69 in the same period last year, representing a growth of approximately 166%[48] - The total profit for the third quarter was CNY 28,618,514.38, compared to CNY 7,763,309.57 in the same quarter last year, marking an increase of about 268.5%[55] Cash Flow - The net cash flow from operating activities increased significantly by 222.74% to CNY 9,674,573.09[7] - Cash flow from operating activities improved significantly to ¥53,901,225.56, a 6669.72% increase compared to the previous year[23] - The net cash flow from operating activities for Q3 2020 was ¥53,901,225.56, a significant improvement compared to a negative cash flow of ¥820,449.64 in Q3 2019, indicating a recovery in operational performance[63] - Total cash inflow from operating activities reached ¥219,856,846.37, up from ¥153,662,527.64 in the same period last year, reflecting a year-over-year increase of approximately 43%[63] - The company reported a net cash outflow from investing activities of ¥34,854,414.43, a decline from a positive cash flow of ¥11,387,224.40 in Q3 2019, highlighting increased investment expenditures[64] - Cash inflow from financing activities was ¥50,966,715.62, compared to ¥15,018,500.00 in Q3 2019, representing a substantial increase of over 238%[64] Assets and Liabilities - Total assets increased by 12.30% to CNY 710,955,847.92 compared to the end of the previous year[7] - The total liabilities increased to CNY 220,852,733.37 from CNY 177,003,294.01, showing a growth in financial obligations[40] - The company's equity attributable to shareholders increased to CNY 452,007,712.55 from CNY 422,651,741.36, reflecting improved financial health[40] - Total assets amounted to CNY 633,081,946.60, with current assets at CNY 286,432,776.45 and non-current assets at CNY 346,649,170.15[70] - Total liabilities reached CNY 177,003,294.01, with current liabilities at CNY 160,914,970.92 and non-current liabilities at CNY 16,088,323.09[72] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 23,138[10] - The top shareholder, Wang Tingchun, holds 35.57% of the shares, amounting to 80,618,642 shares[10] - The company did not engage in any repurchase transactions during the reporting period[11] Research and Development - Research and development expenses rose by 43.36% to ¥16,784,207.58 as the company increased its investment in R&D[19] - Research and development expenses for the quarter were CNY 4,348,126.55, an increase from CNY 3,399,334.52 in the previous period[50] - Research and development expenses for the third quarter amounted to CNY 11,599,267.55, up from CNY 6,844,286.18, reflecting a year-over-year increase of approximately 69.5%[58] Capital and Financing - The company plans to raise up to ¥343.20 million through a non-public offering of A-shares, with a maximum of 67,603,380 shares to be issued[24] - The company reduced its short-term borrowings by 113.27% to ¥31,990,000.00 due to increased bank loans during the period[17] - The company completed the change of its registered capital from ¥174,322,655 to ¥226,619,451 following the capital increase[27] Compliance and Governance - The company reported no violations regarding external guarantees during the reporting period[32] - There were no non-operating fund occupations by controlling shareholders or related parties during the reporting period[33] - The report indicates that the third-quarter financials were not audited, which may affect the reliability of the data presented[78] Future Outlook - Future outlook and performance guidance were not explicitly detailed in the report[79] - The company has not reported any new product developments or market expansions in this quarter[79] - There are no indications of mergers or acquisitions in the current financial report[79]

Financial Performance - The company's operating revenue for the first half of 2020 was CNY 110,045,597.78, representing a 17.93% increase compared to CNY 93,316,182.27 in the same period last year[18]. - The net profit attributable to shareholders of the listed company reached CNY 11,874,953.42, a significant increase of 303.23% from CNY 2,944,975.71 in the previous year[18]. - The net profit after deducting non-recurring gains and losses was CNY 8,991,567.52, up 581.16% from CNY 1,320,038.74 in the same period last year[18]. - The net cash flow from operating activities was CNY 44,226,652.47, an increase of 526.31% compared to CNY 7,061,413.83 in the previous year[18]. - Basic earnings per share increased to CNY 0.0526, a rise of 301.53% from CNY 0.0131 in the previous year[18]. - Total operating revenue for the first half of 2020 reached ¥110,045,597.78, an increase of 17.9% compared to ¥93,316,182.27 in the first half of 2019[153]. - Net profit for the first half of 2020 was ¥14,866,119.67, a significant increase of 354.5% from ¥3,272,443.07 in the same period last year[155]. - The total comprehensive income for the first half of 2020 was ¥15,080,552.18, compared to ¥3,299,938.46 in the same period last year, reflecting a growth of 356.5%[156]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 712,113,224.44, reflecting a 12.48% increase from CNY 633,081,946.60 at the end of the previous year[18]. - The total liabilities increased to CNY 229,731,499.54 from CNY 177,003,294.01, indicating a rise of approximately 29.8%[147]. - The company's total assets at the end of the first half of 2020 were CNY 450.88 million, compared to CNY 422.84 million at the end of the previous year[174]. - The total liabilities at the end of the period were approximately 6,957 million yuan, indicating a manageable debt level[170]. Cash Flow - The net cash flow from operating activities for the first half of 2020 was CNY 44,226,652.47, a significant increase from CNY 7,061,413.83 in the same period of 2019, representing a growth of approximately 527%[162]. - Cash inflow from financing activities totaled CNY 49,966,715.62, a substantial increase from CNY 1,356,628.50 in the first half of 2019[163]. - The ending balance of cash and cash equivalents increased to CNY 96,276,582.68 from CNY 69,841,125.50, representing a growth of about 37.9%[163]. Research and Development - The company is focusing on the development of new drugs and generics, leveraging its technical expertise and industry experience[27]. - The company has provided clinical research services for over 800 projects, helping clients obtain more than 60 new drug certificates and approximately 80 production approvals[36]. - The company’s R&D investment increased by 46.37% to ¥10,737,338.09, indicating a strong commitment to innovation[52]. - The company has established five major R&D service platforms, significantly enhancing its capabilities in preclinical research services[40]. Market Position and Strategy - The company operates as a professional CRO service provider, offering a full range of services including preclinical research, clinical research, and CDMO services[25]. - The global CRO market size reached $57.8 billion in 2018, with a projected CAGR of 10.47% from 2018 to 2023, expected to reach $95.1 billion[29]. - The domestic CRO market size was approximately $5.8 billion in 2018, with a projected CAGR of 29.6% from 2018 to 2023, expected to reach $21.4 billion[30]. - The company is one of the few CROs in China capable of providing full-process "one-stop" services for new drug development[34]. Governance and Compliance - All directors attended the board meeting to review this report, ensuring comprehensive oversight[4]. - The financial report was approved by the board of directors on August 26, 2020[182]. - The company has not engaged in any derivative investments or entrusted loans during the reporting period[68][69]. Risks and Challenges - The company faces risks related to policy changes in the new drug research industry, which could impact its business operations and revenue[73]. - The company is facing increased market competition due to the rapid growth of domestic CRO companies, which necessitates improved marketing and service levels[75]. - The company has implemented measures to mitigate risks associated with long-term contract execution in new drug development[74]. Shareholder Information - The number of shareholders holding more than 5% of ordinary shares includes Wang Tingchun with 35.57% and Zhao Lingli with 8.87%[125]. - The total number of ordinary shareholders at the end of the reporting period was 10,096[125]. - The company has implemented a stock option incentive plan, with the first exercise period completed in 2019[120]. Miscellaneous - The company has not engaged in any poverty alleviation initiatives during the reporting period and has no plans for future initiatives[107]. - The company has not conducted any major litigation or arbitration matters during the reporting period[85]. - The company has not received any penalties or corrective actions during the reporting period[87].

Financial Performance - Total revenue for Q1 2020 was ¥20,818,697.66, a decrease of 42.65% compared to ¥36,303,568.42 in the same period last year[7] - Net profit attributable to shareholders was -¥5,863,094.83, representing a decline of 523.55% from ¥1,384,278.97 in the previous year[7] - Basic earnings per share were -¥0.0338, a decrease of 522.50% compared to ¥0.0080 in the previous year[7] - The net profit for the first quarter of 2020 was -5,118,325.78 CNY, compared to a net profit of 3,225,347.69 CNY in the same period last year, indicating a significant decline[54] - Operating profit for the first quarter was -6,293,827.61 CNY, down from an operating profit of 3,784,010.77 CNY in the previous year[54] - The company’s total comprehensive income for the first quarter was -5,118,325.78 CNY, compared to 3,225,347.69 CNY in the same period last year[55] Cash Flow and Liquidity - The net cash flow from operating activities was -¥529,616.16, down 110.98% from ¥4,822,967.12 in the same period last year[7] - Cash flow from operating activities showed a net outflow of -529,616.16 CNY, a decrease from a net inflow of 4,822,967.12 CNY in the same quarter last year[58] - The company received cash inflows from operating activities totaling 44,149,562.53 CNY, slightly down from 46,839,241.23 CNY in the previous year[57] - The company reported cash outflows from operating activities of 44,679,178.69 CNY, compared to 42,016,274.11 CNY in the same period last year[58] - The company’s cash and cash equivalents increased to CNY 80,808,720.47 from CNY 57,350,018.69, representing a growth of about 40.9%[40] - The total cash and cash equivalents at the end of the period amounted to 80,808,720.47 CNY, compared to 83,134,956.71 CNY at the end of the previous year[59] Assets and Liabilities - Total assets at the end of the reporting period were ¥651,513,808.74, an increase of 2.91% from ¥633,081,946.60 at the end of the previous year[7] - The company’s total liabilities increased to CNY 197,884,906.02 from CNY 177,003,294.01, marking an increase of approximately 11.2%[42] - The equity attributable to the owners of the parent company decreased slightly to CNY 419,817,828.66 from CNY 422,651,741.36, a decline of about 0.8%[43] - Accounts receivable decreased significantly from CNY 78,074,241.48 to CNY 39,354,037.11, a reduction of approximately 49.7%[40] - Inventory levels rose to CNY 99,574,851.87, up from CNY 91,510,732.40, indicating an increase of about 8.8%[40] Research and Development - The company reported a significant increase in R&D expenses, which rose by 100.65% to CNY 4,900,656.34, reflecting a commitment to enhancing research and development efforts[16] - Research and development expenses increased to CNY 4,900,656.34, up from CNY 2,442,403.77 in the previous period, reflecting a focus on innovation[49] Government Support and Subsidies - The company received government subsidies amounting to ¥2,056,138.71 during the reporting period[8] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 9,781[10] - The largest shareholder, Wang Tingchun, holds 35.78% of the shares, with 46,510,755 shares pledged[10] Business Strategy and Market Position - The company is focused on resuming project progress as the domestic pandemic situation improves, while continuing to respond to government calls for pandemic control[19] - The company plans to leverage its unique "one-stop" service advantage to adjust its business structure and enhance its ability to withstand risks due to potential policy changes in the new drug approval process[24] - The company is expanding its business into preclinical research services and CDMO services, facing competition from established companies in these fields[29] - The company is focusing on expanding its market presence and enhancing product development capabilities[49] - Future outlook indicates a commitment to improving financial performance and exploring strategic partnerships for growth[49] Risk Management - The company has implemented measures to mitigate risks associated with long contract execution periods in new drug development, including setting conditions for additional service fees[25] - The company has established a communication mechanism with clients to address unexpected situations during contract execution, aiming for win-win outcomes[26] - The company is enhancing internal management and integrating efforts to improve operational efficiency as it expands its business scale[27] Compliance and Governance - The company has no overdue commitments from major shareholders or related parties during the reporting period[34] - There were no violations regarding external guarantees during the reporting period[35] - The company has not reported any non-operating fund occupation by major shareholders or related parties[36] - The first quarter report for 2020 was not audited, indicating potential limitations in the reliability of the financial data presented[70] - The legal representative of the company is Wang Tingchun, as of April 24, 2020[71]

Dividend Distribution - The company plans to distribute a cash dividend of 0.1 yuan per 10 shares and a capital reserve increase of 3 shares per 10 shares based on a base of 173,342,000 shares[6]. - A cash dividend of RMB 0.1 per share (totaling RMB 1,733,420) will be distributed, with a capital reserve conversion of 3 shares for every 10 shares held[113]. - The cash dividend payout ratio for 2019 was 26.29% of the net profit attributable to shareholders[120]. - The cash dividend payout ratio for 2018 was 27.15% of the net profit attributable to shareholders[120]. - The total cash dividends distributed in 2019 amounted to RMB 1,733,420.00, while the total for 2018 was RMB 2,008,762.50[120]. - In 2015, the company distributed a cash dividend of RMB 0.50 per 10 shares, totaling RMB 6,667,000.00[116]. - No cash dividends were distributed for the years 2016 and 2017, nor were there any stock bonuses or capital reserve transfers[116][117]. - In 2018, the company distributed a cash dividend of RMB 0.15 per 10 shares, totaling RMB 2,008,762.50, and issued 40,175,250 bonus shares[118]. - For 2019, the proposed cash dividend was RMB 0.10 per 10 shares, totaling RMB 1,733,420.00, along with a transfer of 52,002,600 bonus shares[118]. Financial Performance - The company's operating revenue for 2019 was RMB 224,064,704.39, representing a 30.24% increase compared to RMB 172,042,840.49 in 2018[19]. - The net profit attributable to shareholders for 2019 was RMB 6,592,620.34, a decrease of 10.91% from RMB 7,399,910.67 in the previous year[19]. - The net profit after deducting non-recurring gains and losses was RMB 1,837,396.93, down 52.94% from RMB 3,904,677.45 in 2018[19]. - The net cash flow from operating activities was RMB 85,874.81, a significant decline of 99.68% compared to RMB 27,059,863.81 in the previous year[19]. - The total assets at the end of 2019 were RMB 633,081,946.60, an increase of 4.47% from RMB 606,022,667.36 at the end of 2018[19]. - The net assets attributable to shareholders at the end of 2019 were RMB 422,651,741.36, up 2.45% from RMB 412,547,766.99 in 2018[19]. - The company reported a basic earnings per share of RMB 0.0380, down 11.01% from RMB 0.0427 in 2018[19]. - The company achieved total revenue of ¥224,064,704.39 in 2019, representing a year-on-year growth of 30.24%[54]. - The net profit attributable to the parent company was ¥6,592,620.34, a decrease of 10.91% compared to the previous year[54]. Business Strategy and Development - The company aims to enhance its risk resistance by developing innovative drug clinical services and preclinical services, leveraging its industry experience and talent advantages[4]. - The company is focusing on developing new business areas such as preclinical research services and CDMO services, facing potential challenges due to existing competitive players in the market[6]. - The company is committed to adjusting its business structure and development direction in response to changes in drug approval policies by NMPA[4]. - The company aims to meet customer needs and accelerate drug development processes to benefit patient health[28]. - The company is focusing on establishing partnerships with multinational pharmaceutical companies for international multi-center clinical research services[102]. - The company plans to invest in healthcare product R&D and pursue mergers and acquisitions to enhance its industry layout and core competitiveness[104]. - The company will continue to develop its CDMO services and expand its business chain in the R&D and production service areas[104]. - The company aims to integrate its services from drug research to production, establishing a one-stop CRO service model[101]. - The company plans to focus on the CRO industry, aiming to develop a comprehensive new drug research platform over the next three to five years[101]. Risk Management - The company acknowledges the risk of contract execution delays due to the complexity of new drug development, which may lead to budget management challenges and potential cost overruns[5]. - The company has established a risk-sharing mechanism in contracts to address potential losses due to unforeseen circumstances during the execution of long-term projects[5]. - The company recognizes the need for careful project evaluation and strict process management to minimize project delays and associated penalties[5]. - The company anticipates potential risks from policy changes affecting new drug approvals and will adjust its business structure accordingly[105]. - The company is enhancing its management capabilities to mitigate risks associated with expanding its operational scale and business scope[108]. Market Trends and Competition - The rapid growth of domestic CRO companies has intensified competition in the pharmaceutical R&D outsourcing industry, necessitating improved marketing and service levels[5]. - The global CRO industry market size reached $57.8 billion in 2018, with a projected growth to $95.1 billion by 2023, reflecting a CAGR of 10.47% from 2018 to 2023[32]. - The domestic CRO market size was approximately $5.8 billion in 2018, with expectations to grow to $21.4 billion by 2023, indicating a CAGR of 29.6% during the same period[33]. - The CRO industry in China is entering a golden era, driven by the shift of global pharmaceutical outsourcing orders to the Asia-Pacific region and the cost advantages from local engineering talent[33]. Operational Efficiency - The company emphasizes the importance of internal management and integration to improve operational efficiency as it scales its business[6]. - The company has developed a nationwide service network, facilitating high-frequency monitoring of clinical research processes[45]. - The company has implemented a standardized quality control system, improving the reliability and efficiency of clinical research services[42]. - The company aims to expand its clinical research service network and enhance quality control to solidify its competitive edge in the clinical research sector[102]. Research and Development - The company has engaged in some preclinical independent research and technology transformation services based on market trends and technical expertise[28]. - The company has developed multiple new drug and generic drug projects through independent research, leveraging its technical expertise and market trends[30]. - The company is conducting IND research for the targeted therapy drug RUNNOR9591 for drug-resistant lung cancer, which has received clinical research permission[78]. - The company has made significant advancements in inhalation formulations, completing efficacy studies for asthma treatment nebulizers[79]. - Research and development expenses increased by 35.56% to CNY 18,279,480.95, reflecting the company's increased investment in R&D[76]. - The company invested approximately ¥18.28 million in R&D in 2019, representing 8.16% of its operating revenue, an increase from 7.84% in 2018[81]. Subsidiaries and Investments - The company established a new wholly-owned subsidiary, Guangdong Guangji Investment Co., Ltd., during the reporting period[71]. - The company established a joint venture, Shenzhen Chenji Pharmaceutical Technology Co., Ltd., with a registered capital of RMB 30 million, in which the company holds a 10% stake[168]. - The company completed a capital increase for its subsidiary, Guangzhou Boji Biomedical Technology Park Co., Ltd., with the registered capital increasing from 112 million RMB to 121.57 million RMB, reducing the company's ownership from 100% to 94.59%[166]. - The company invested in establishing a new subsidiary, Xinxiang Boji Pharmaceutical Technology Co., Ltd., with a registered capital of 10 million RMB, of which the company contributed 8 million RMB (80%)[166]. Management and Governance - The company has maintained a stable management structure with no significant turnover in key positions over the past year[200]. - The management team includes 10 members, with a mix of roles including independent directors and supervisors[198]. - The average age of the senior management team is approximately 47 years, indicating a relatively experienced leadership[198]. - Wang Tingchun serves as both the chairman and general manager of the company[190]. - The company appointed Wei Fangqun as the new Secretary of the Board on October 28, 2019, following the resignation of Han Yuping[200].

Financial Performance - Operating revenue for the reporting period was CNY 48,786,229.04, representing a year-on-year increase of 33.98%[7] - Net profit attributable to shareholders was CNY 2,658,217.91, a significant increase of 588.26% compared to the same period last year[7] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 1,290,363.54, up 290.47% year-on-year[7] - Basic earnings per share for the reporting period were CNY 0.0153, an increase of 595.45% compared to the same period last year[7] - Total operating revenue for Q3 2019 was CNY 48,786,229.04, an increase of 34% compared to CNY 36,413,303.19 in the same period last year[39] - Net profit for Q3 2019 reached CNY 3,600,393.69, a significant increase from CNY 1,796,981.31 in Q3 2018, representing a growth of 100%[40] - Earnings per share for Q3 2019 were CNY 0.0153, compared to CNY 0.0022 in the same quarter last year, reflecting a substantial increase[41] Assets and Liabilities - Total assets at the end of the reporting period were CNY 605,047,812.12, a decrease of 0.16% compared to the end of the previous year[7] - The company's current assets totaled CNY 267,740,071.04, down from CNY 281,618,574.83 at the end of 2018, representing a decrease of approximately 4.5%[29] - The company's total liabilities decreased to CNY 173,723,425.33 from CNY 182,309,914.41, a reduction of about 4.8%[31] - Short-term borrowings increased significantly to CNY 15,000,000.00 from CNY 7,665,419.80, representing an increase of about 96.2%[31] - The total liabilities decreased to CNY 131,203,766.59 from CNY 140,277,714.82 year-over-year, indicating a reduction of approximately 6%[37] - Total equity increased to CNY 427,896,746.19 from CNY 422,842,742.28, showing a slight growth of about 1%[37] Cash Flow - The company reported a net cash flow from operating activities of -CNY 820,449.64, a decrease of 124.48% compared to the same period last year[7] - The net cash flow from operating activities decreased by 124.48% to -¥820,449.64 from ¥3,351,380.44, mainly due to increased cost expenses[17] - The net cash flow from investment activities improved by 114.48% to ¥11,387,224.40 from -¥78,651,665.42, mainly due to the expiration of financial products[17] - Cash inflow from operating activities amounted to CNY 153,662,527.64, an increase from CNY 132,398,839.14 in the previous period[54] - The net cash flow from operating activities was negative at CNY -820,449.64, down from CNY 3,351,380.44 in the previous period[55] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 16,072[10] - The largest shareholder, Wang Tingchun, held 35.78% of the shares, amounting to 62,014,340 shares[10] - The company reported no overdue commitments from controlling shareholders or related parties during the reporting period[25] - There were no violations regarding external guarantees during the reporting period[25] - The company did not execute any cash dividend policy during the reporting period[25] Government Subsidies and Other Income - The company received government subsidies amounting to CNY 2,785,066.76 during the reporting period[8] - The company reported a 90.51% increase in other income to ¥2,778,174.10 from ¥1,458,288.39, attributed to government subsidies related to daily operations[16] - The company reported a significant increase in other income, which rose to CNY 1,421,427.75 from CNY 971,189.71 in the previous year, marking a growth of 46%[39] Research and Development - Research and development expenses for Q3 2019 amounted to CNY 4,371,600.50, which is a 17% increase from CNY 3,728,231.70 in Q3 2018[39] - Research and development expenses increased to ¥11,707,456.13, up 26.0% from ¥9,299,376.64 year-on-year[45] Strategic Initiatives - The company plans to continue expanding its market presence and investing in new product development to drive future growth[40] - The company is actively pursuing market expansion strategies, including potential mergers and acquisitions to enhance its competitive position in the biotechnology sector[63] - New product development initiatives are underway, aimed at leveraging technological advancements to improve product offerings and market reach[63] - The management emphasized the importance of maintaining financial stability while exploring innovative strategies for growth and market penetration[63]